Bradley Pharmaceuticals, Inc. - BDY- Profile

Bradley Pharmaceuticals, Inc.. The Group's principal activities are to acquire, develop and market prescription and over-the-counter products in niche therapeutic markets. The Group serves the dermatology, podiatry, gastroenterology and women's health market through its subsidiaries. The Group operates in two segments: Doak Dermatologics and Kenwood Therapeutics. The Doak Dermatologics segment develops therapies for dermatology and podiatry. The Products of the Doak Dermatologics segment include ADOXA(R), KERALAC(R)/ KEROLTM, SOLARAZE(R), ZODERM(R), LIDAMANTLE(R), and ROSULA(R) .The Kenwood Therapeutics markets the nutritional supplements, gastroenterology, women's health, respiratory and other internal medicine brands. The Products of the Kenwood Therapeutics include PAMINE(R), ANAMANTLE(R) HC and FLORA-Q(R). The Group operates in the United States. Doak Dermatologics accounted for 80% of 2006 revenues and Kenwood Therapeutics, 20%